Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat ...

Merck's Keytruda receives FDA approval for head and neck cancer after showing improved event-free survival in Phase 3 KEYNOTE ...

Citizens Financial Group (CFG) will be expanding its share buyback program to $1.5 billion. Pharmaceutical giant Merck (MRK) ...

The Rahway, N.J., drug maker said Friday that its treatment, Keytruda, has been approved for adult patients with resectable locally advanced head and neck squamous cell carcinoma whose tumors express ...

Merck (MRK) on Friday said that the U.S. Food and Drug Administration (FDA) has approved its blockbuster drug Keytruda for ...

Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable ...

Keytruda marks the first perioperative anti-PD-1 treatment option for adults with PD-L1–positive resectable locally advanced ...

RESVIA is now authorized for use in adults aged 18–59 years with an increased risk of respiratory syncytial virus-related ...

Merck also introduces the first perioperative anti-PD-1 treatment regimen for adults with resectable locally advanced head ...

RayzeBio, the radiopharmaceutical unit of Bristol Myers Squibb, licensed an experimental drug and diagnostic agent for prostate cancer from Philochem AG for a $350 million upfront payment. Philochem ...

In a major boost for infant health, the U.S. Food and Drug Administration (FDA) has approved ENFLONSIA ™ (clesrovimab-cfor), ...

Martin Kulldorff and Robert Malone, both outspoken vaccine skeptics, have received compensation for their expert ...